Global Reappraisal of HBV and HCV Attribution in Hepatocellular Carcinoma: a systematic review and meta-analysis of 878,083 patients reveals a recent resurgence
This systematic review and meta-analysis of 878,083 patients reveals that while HBV and HCV remain the dominant global causes of hepatocellular carcinoma with distinct geographic distributions, their temporal trends show a recent resurgence of HBV-associated cases after 2010 and a post-2005 decline in HCV-associated cases, underscoring the need for continued surveillance despite prevention advances.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Liver cancer is a relentless disease that claims millions of lives worldwide, but for decades, scientists have known that two specific viruses are the primary architects of this tragedy. One is the hepatitis B virus, a microscopic invader that can hide in the liver for years, slowly damaging the organ's structure. The other is the hepatitis C virus, which behaves differently, often causing inflammation that leads to scarring over time. While medical advances like vaccines and powerful new drugs have successfully reduced the threat of these viruses in many parts of the world, the story of how they cause liver cancer is not a simple tale of steady decline. Instead, the landscape is shifting in complex ways that depend heavily on where a person lives and how old they are. Understanding these patterns is critical because the strategies used to prevent liver cancer must match the current reality of the viruses, not just the reality of the past.
A massive new study has just mapped out this changing world by looking at nearly 880,000 patients with liver cancer from 60 different countries. The researchers gathered data from hundreds of existing medical reports to create the most complete picture yet of how often these two viruses appear in cancer patients today. Their work reveals that while the viruses remain the leading cause of liver cancer globally, their influence is not fading uniformly. In fact, the data shows a surprising twist: after years of decline, the share of liver cancer cases linked to the hepatitis B virus has begun to rise again in recent years. Meanwhile, the pattern for hepatitis C is far more complicated, rising and falling in a distinct wave-like shape over the last few decades rather than following a straight line down.
The study, which analyzed records spanning from the late 1950s to early 2026, found that globally, about half of all liver cancer cases are driven by the hepatitis B virus, while roughly a quarter are caused by hepatitis C. However, these numbers tell very different stories depending on the region. In East Asia, Southeast Asia, and sub-Saharan Africa, the hepatitis B virus remains the dominant force, responsible for the vast majority of cases. In contrast, in North Africa, the Middle East, and high-income countries in North America, the hepatitis C virus is the more common culprit. The researchers also looked at how these patterns have changed over time. They discovered that the proportion of liver cancer caused by hepatitis B dropped steadily from the 1990s until around 2010, but then started to climb back up. This resurgence is a significant finding because it challenges the long-held belief that the problem is simply getting smaller everywhere.
The reasons behind this unexpected rebound are likely a mix of factors. One possibility is that as treatments for hepatitis C have become highly effective, the number of liver cancer cases caused by that virus has dropped sharply, making the hepatitis B cases stand out more by comparison. Another factor is the aging of populations in countries where the virus is common. Many people born before widespread vaccination programs began are now reaching the age where liver cancer typically strikes, keeping the numbers of hepatitis B-related cases high. The study also highlighted a striking difference in the age of patients. Liver cancer driven by hepatitis B tends to appear in people in their early 50s, whereas cancer caused by hepatitis C usually shows up in people in their late 60s. This gap suggests that the two viruses damage the liver through different biological paths, with one acting more aggressively and earlier in life.
The research also examined the rare but dangerous situation where a patient is infected with both viruses at the same time. This co-infection was found to be most common in Central Asia and Eastern Europe, where it accounts for a significantly higher percentage of cases than in other parts of the world. When both viruses are present, the risk of developing cancer increases dramatically, and the disease progresses faster. The study found that the rate of these double infections has been slowly declining, but the high concentration in specific regions means that screening strategies in those areas need to be particularly thorough.
Perhaps the most important takeaway from this global review is that the fight against liver cancer cannot rely on a single strategy that works the same way everywhere. The data shows that while vaccines for children have been successful in many places, the virus has not disappeared from the adult population. The recent uptick in hepatitis B cases suggests that public health efforts need to expand beyond childhood immunization to include aggressive screening and treatment for adults, particularly those in their 30s to 60s in high-risk areas. Similarly, the fluctuating pattern of hepatitis C indicates that vigilance must remain high, as the virus can resurge if prevention efforts slip. By providing a clear, up-to-date map of where these viruses are and how they are behaving, this study offers a crucial guide for doctors and policymakers. It reminds us that while medical science has made incredible progress, the battle against liver cancer requires constant adaptation to the changing nature of the enemy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.